The role of the methyltransferase METTL3 in prostate cancer: a potential therapeutic target

被引：0
作者：
Xuming Zhou
Keqiang Chai
Hezhen Zhu
Cong Luo
Xiaofeng Zou
Junrong Zou
Guoxi Zhang
机构：
[1] Gannan Medical University,First Clinical College
[2] First Affiliated Hospital of Gannan Medical University,Department of Urology
[3] Third Affiliated Hospital of Gansu University of Chinese Medicine,Department of Urology
[4] First Affiliated Hospital of Gannan Medical University,Institute of Urology
[5] Jiangxi Engineering Technology Research Center of Calculi Prevention,undefined
来源：
BMC Cancer | / 24卷
关键词：
METTL3; Prostate cancer; m6A; Drug-resistance; Biomarker;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
The incidence of prostate cancer (PCa), the most prevalent malignancy, is currently at the forefront. RNA modification is a subfield of the booming field of epigenetics. To date, more than 170 types of RNA modifications have been described, and N6-methyladenosine (m6A) is the most abundant and well-characterized internal modification of mRNAs involved in various aspects of cancer progression. METTL3, the first identified key methyltransferase, regulates human mRNA and non-coding RNA expression in an m6A-dependent manner. This review elucidates the biological function and role of METTL3 in PCa and discusses the implications of METTL3 as a potential therapeutic target for future research directions and clinical applications.
引用
收藏
相关论文
共 810 条
[1]  
Sung H(2021)Global cancer statistics 2020: globocan estimates of incidence and mortality worldwide for 36 cancers in 185 countries CA Cancer J Clin. 71 209-249
[2]  
Ferlay J(2018)Global cancer statistics 2018: globocan estimates of incidence and mortality worldwide for 36 cancers in 185 countries CA Cancer J Clin. 68 394-424
[3]  
Siegel RL(2017)Global burden of urologic cancers, 1990-2013 Eur Urol. 71 437-446
[4]  
Bray F(2016)Global incidence and mortality for prostate cancer: analysis of temporal patterns and trends in 36 countries Eur Urol. 70 862-874
[5]  
Ferlay J(2022)Management of patients with advanced prostate cancer: report from the advanced prostate cancer consensus conference 2021 Eur Urol. 82 115-141
[6]  
Soerjomataram I(2019)Treatment of advanced prostate cancer Annu Rev Med. 70 479-499
[7]  
Siegel RL(2017)Androgen deprivation and immunotherapy for the treatment of prostate cancer Endocr Relat Cancer. 24 t297-t310
[8]  
Torre LA(1974)Identification of methylated nucleosides in messenger rna from novikoff hepatoma cells Proc Natl Acad Sci U S A. 71 3971-3975
[9]  
Jemal A(2015)Rna n6-methyladenosine methylation in post-transcriptional gene expression regulation Genes Dev. 29 1343-1355
[10]  
Dy GW(2023)M6a-and immune-related lncrna signature confers robust predictive power for immune efficacy in lung squamous cell carcinoma View. 4 20220083-206
12345678910